{"id":760806,"date":"2023-05-30T16:04:51","date_gmt":"2023-05-30T20:04:51","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/seres-therapeutics-announces-receipt-of-125-million-milestone-from-nestle-health-science-following-fda-approval-of-vowst\/"},"modified":"2023-05-30T16:04:51","modified_gmt":"2023-05-30T20:04:51","slug":"seres-therapeutics-announces-receipt-of-125-million-milestone-from-nestle-health-science-following-fda-approval-of-vowst","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/seres-therapeutics-announces-receipt-of-125-million-milestone-from-nestle-health-science-following-fda-approval-of-vowst\/","title":{"rendered":"Seres Therapeutics Announces Receipt of $125 Million Milestone From Nestl\u00e9 Health Science Following FDA Approval of VOWST\u2122"},"content":{"rendered":"

<\/p>\n

Seres Therapeutics Announces Receipt of $125 Million Milestone From Nestl\u00e9 Health Science Following FDA Approval of VOWST\u2122<\/b><\/p>\n

CAMBRIDGE, Mass.–(BUSINESS WIRE<\/a>)–Seres Therapeutics, Inc.<\/a> (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that the Company has received a $125 million milestone payment from Nestl\u00e9 Health Science related to the U.S. Food and Drug Administration approval of VOWST\u2122 (fecal microbiota spores, live-brpk), an orally administered microbiota-based therapeutic to prevent recurrence of C. difficile<\/i> Infection (CDI) in adults following antibiotic treatment for recurrent CDI.<\/p>\n

\nThe approval milestone follows the July 2021 agreement between Seres and Nestl\u00e9 Health Science to jointly commercialize VOWST in the U.S. and Canada. Following VOWST commercialization, each company will be entitled to share equally in commercial profits and losses. In addition, Seres is eligible to receive payments of up to $225 million for the achievement of specified net sales milestones.<\/p>\n

INDICATION AND IMPORTANT SAFETY INFORMATION FOR VOWST<\/b><\/p>\n

INDICATION<\/b><\/p>\n

\nVOWST is indicated to prevent the recurrence of Clostridioides difficile<\/i> infection (CDI) in individuals 18 years of age and older following antibacterial treatment for recurrent CDI (rCDI).<\/p>\n

\nLimitation of Use: VOWST is not indicated for treatment of CDI.<\/p>\n

IMPORTANT SAFETY INFORMATION<\/b><\/p>\n

WARNINGS AND PRECAUTIONS<\/b><\/p>\n

Transmissible infectious agents:<\/b> Because VOWST is manufactured from human fecal matter, it may carry a risk of transmitting infectious agents. Report any infection that is suspected to have been transmitted by VOWST to Aimmune Therapeutics, Inc. at 1-833-246-2566.<\/p>\n

Potential presence of food allergens: <\/b>VOWST may contain food allergens. The potential to cause adverse reactions due to food allergens is unknown.<\/p>\n

ADVERSE REACTIONS<\/b><\/p>\n

\nThe most common adverse reactions (reported in \u22655% of participants) were abdominal distension (31.1%), fatigue (22.2%), constipation (14.4%), chills (11.1%), and diarrhea (10.0%).<\/p>\n

\nTo report SUSPECTED ADVERSE REACTIONS, contact Aimmune Therapeutics at 1-833-AIM-2KNO (1-833-246-2566), or the FDA at 1-800-FDA-1088, or visit www.fda.gov\/MedWatch<\/a>.<\/p>\n

DRUG INTERACTIONS<\/b><\/p>\n

\nDo not administer antibacterials concurrently with VOWST.<\/p>\n

Please see <\/b>Full Prescribing Information<\/b><\/a> and <\/b>Patient Information<\/b><\/a><\/p>\n

About Seres Therapeutics<\/b><\/p>\n

\nSeres Therapeutics, Inc. (Nasdaq: MCRB) is a commercial-stage company developing novel microbiome therapeutics for serious diseases. Seres\u2019 lead program, VOWSTTM<\/sup>, obtained U.S. FDA approval in April 2023 as the first orally administered microbiota-based therapeutic to prevent recurrence of C. difficile<\/i> infection (CDI) in adults following antibacterial treatment for recurrent CDI and is being commercialized in collaboration with Nestl\u00e9 Health Science. Seres is evaluating SER-155 in a Phase 1b study in patients receiving allogeneic hematopoietic stem cell transplantation to reduce incidences of gastrointestinal infections, bloodstream infections and graft-versus-host disease as well as additional preclinical stage programs targeting Infection Protection in medically compromised patients. The Company is also conducting research to inform further development of microbiome therapeutics for ulcerative colitis. For more information, please visit www.serestherapeutics.com<\/a>.<\/p>\n

Forward-Looking Statements<\/b><\/p>\n

\nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including our ability to achieve sales targets, the receipt of future milestone payments, and other statements which are not historical fact.<\/p>\n

\nThese forward-looking statements are based on management\u2019s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: we are not currently profitable and may never become profitable, our reliance on collaborators to commercialize VOWST, and the unknown degree of market acceptance of VOWST. These and other important factors discussed under the caption \u201cRisk Factors\u201d in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC), on May 9, 2023, and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management\u2019s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20230530005506\/en\/<\/a><\/span><\/p>\n

IR and PR:
\n<\/b>
Carlo Tanzi, Ph.D.
\n
ctanzi@serestherapeutics.com<\/a><\/p>\n

KEYWORDS:<\/b> United States North America Massachusetts<\/p>\n

INDUSTRY KEYWORDS:<\/b> Health FDA Stem Cells Research Science Pharmaceutical Biotechnology<\/p>\n

MEDIA:<\/b><\/p>\n\n","protected":false},"excerpt":{"rendered":"

Seres Therapeutics Announces Receipt of $125 Million Milestone From Nestl\u00e9 Health Science Following FDA Approval of VOWST\u2122 CAMBRIDGE, Mass.–(BUSINESS WIRE)–Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that the Company has received a $125 million milestone payment from Nestl\u00e9 Health Science related to the U.S. Food and Drug Administration approval of VOWST\u2122 (fecal microbiota spores, live-brpk), an orally administered microbiota-based therapeutic to prevent recurrence of C. difficile Infection (CDI) in adults following antibiotic treatment for recurrent CDI. The approval milestone follows the July 2021 agreement between Seres and Nestl\u00e9 Health Science to jointly commercialize VOWST in the U.S. and Canada. Following VOWST commercialization, each company will be entitled to share equally in commercial profits and losses. … <\/p>\n

Continue reading “Seres Therapeutics Announces Receipt of $125 Million Milestone From Nestl\u00e9 Health Science Following FDA Approval of VOWST\u2122”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-760806","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nSeres Therapeutics Announces Receipt of $125 Million Milestone From Nestl\u00e9 Health Science Following FDA Approval of VOWST\u2122 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/seres-therapeutics-announces-receipt-of-125-million-milestone-from-nestle-health-science-following-fda-approval-of-vowst\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Seres Therapeutics Announces Receipt of $125 Million Milestone From Nestl\u00e9 Health Science Following FDA Approval of VOWST\u2122 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Seres Therapeutics Announces Receipt of $125 Million Milestone From Nestl\u00e9 Health Science Following FDA Approval of VOWST\u2122 CAMBRIDGE, Mass.–(BUSINESS WIRE)–Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that the Company has received a $125 million milestone payment from Nestl\u00e9 Health Science related to the U.S. Food and Drug Administration approval of VOWST\u2122 (fecal microbiota spores, live-brpk), an orally administered microbiota-based therapeutic to prevent recurrence of C. difficile Infection (CDI) in adults following antibiotic treatment for recurrent CDI. The approval milestone follows the July 2021 agreement between Seres and Nestl\u00e9 Health Science to jointly commercialize VOWST in the U.S. and Canada. Following VOWST commercialization, each company will be entitled to share equally in commercial profits and losses. … Continue reading "Seres Therapeutics Announces Receipt of $125 Million Milestone From Nestl\u00e9 Health Science Following FDA Approval of VOWST\u2122"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/seres-therapeutics-announces-receipt-of-125-million-milestone-from-nestle-health-science-following-fda-approval-of-vowst\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-30T20:04:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230530005506r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seres-therapeutics-announces-receipt-of-125-million-milestone-from-nestle-health-science-following-fda-approval-of-vowst\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seres-therapeutics-announces-receipt-of-125-million-milestone-from-nestle-health-science-following-fda-approval-of-vowst\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Seres Therapeutics Announces Receipt of $125 Million Milestone From Nestl\u00e9 Health Science Following FDA Approval of VOWST\u2122\",\"datePublished\":\"2023-05-30T20:04:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seres-therapeutics-announces-receipt-of-125-million-milestone-from-nestle-health-science-following-fda-approval-of-vowst\\\/\"},\"wordCount\":778,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seres-therapeutics-announces-receipt-of-125-million-milestone-from-nestle-health-science-following-fda-approval-of-vowst\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230530005506r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seres-therapeutics-announces-receipt-of-125-million-milestone-from-nestle-health-science-following-fda-approval-of-vowst\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seres-therapeutics-announces-receipt-of-125-million-milestone-from-nestle-health-science-following-fda-approval-of-vowst\\\/\",\"name\":\"Seres Therapeutics Announces Receipt of $125 Million Milestone From Nestl\u00e9 Health Science Following FDA Approval of VOWST\u2122 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seres-therapeutics-announces-receipt-of-125-million-milestone-from-nestle-health-science-following-fda-approval-of-vowst\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seres-therapeutics-announces-receipt-of-125-million-milestone-from-nestle-health-science-following-fda-approval-of-vowst\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230530005506r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2023-05-30T20:04:51+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seres-therapeutics-announces-receipt-of-125-million-milestone-from-nestle-health-science-following-fda-approval-of-vowst\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seres-therapeutics-announces-receipt-of-125-million-milestone-from-nestle-health-science-following-fda-approval-of-vowst\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seres-therapeutics-announces-receipt-of-125-million-milestone-from-nestle-health-science-following-fda-approval-of-vowst\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230530005506r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230530005506r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seres-therapeutics-announces-receipt-of-125-million-milestone-from-nestle-health-science-following-fda-approval-of-vowst\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Seres Therapeutics Announces Receipt of $125 Million Milestone From Nestl\u00e9 Health Science Following FDA Approval of VOWST\u2122\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Seres Therapeutics Announces Receipt of $125 Million Milestone From Nestl\u00e9 Health Science Following FDA Approval of VOWST\u2122 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/seres-therapeutics-announces-receipt-of-125-million-milestone-from-nestle-health-science-following-fda-approval-of-vowst\/","og_locale":"en_US","og_type":"article","og_title":"Seres Therapeutics Announces Receipt of $125 Million Milestone From Nestl\u00e9 Health Science Following FDA Approval of VOWST\u2122 - Market Newsdesk","og_description":"Seres Therapeutics Announces Receipt of $125 Million Milestone From Nestl\u00e9 Health Science Following FDA Approval of VOWST\u2122 CAMBRIDGE, Mass.–(BUSINESS WIRE)–Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that the Company has received a $125 million milestone payment from Nestl\u00e9 Health Science related to the U.S. Food and Drug Administration approval of VOWST\u2122 (fecal microbiota spores, live-brpk), an orally administered microbiota-based therapeutic to prevent recurrence of C. difficile Infection (CDI) in adults following antibiotic treatment for recurrent CDI. The approval milestone follows the July 2021 agreement between Seres and Nestl\u00e9 Health Science to jointly commercialize VOWST in the U.S. and Canada. Following VOWST commercialization, each company will be entitled to share equally in commercial profits and losses. … Continue reading \"Seres Therapeutics Announces Receipt of $125 Million Milestone From Nestl\u00e9 Health Science Following FDA Approval of VOWST\u2122\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/seres-therapeutics-announces-receipt-of-125-million-milestone-from-nestle-health-science-following-fda-approval-of-vowst\/","og_site_name":"Market Newsdesk","article_published_time":"2023-05-30T20:04:51+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230530005506r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seres-therapeutics-announces-receipt-of-125-million-milestone-from-nestle-health-science-following-fda-approval-of-vowst\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seres-therapeutics-announces-receipt-of-125-million-milestone-from-nestle-health-science-following-fda-approval-of-vowst\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Seres Therapeutics Announces Receipt of $125 Million Milestone From Nestl\u00e9 Health Science Following FDA Approval of VOWST\u2122","datePublished":"2023-05-30T20:04:51+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seres-therapeutics-announces-receipt-of-125-million-milestone-from-nestle-health-science-following-fda-approval-of-vowst\/"},"wordCount":778,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seres-therapeutics-announces-receipt-of-125-million-milestone-from-nestle-health-science-following-fda-approval-of-vowst\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230530005506r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seres-therapeutics-announces-receipt-of-125-million-milestone-from-nestle-health-science-following-fda-approval-of-vowst\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/seres-therapeutics-announces-receipt-of-125-million-milestone-from-nestle-health-science-following-fda-approval-of-vowst\/","name":"Seres Therapeutics Announces Receipt of $125 Million Milestone From Nestl\u00e9 Health Science Following FDA Approval of VOWST\u2122 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seres-therapeutics-announces-receipt-of-125-million-milestone-from-nestle-health-science-following-fda-approval-of-vowst\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seres-therapeutics-announces-receipt-of-125-million-milestone-from-nestle-health-science-following-fda-approval-of-vowst\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230530005506r1&sid=flmnd&distro=nx&lang=en","datePublished":"2023-05-30T20:04:51+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seres-therapeutics-announces-receipt-of-125-million-milestone-from-nestle-health-science-following-fda-approval-of-vowst\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/seres-therapeutics-announces-receipt-of-125-million-milestone-from-nestle-health-science-following-fda-approval-of-vowst\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seres-therapeutics-announces-receipt-of-125-million-milestone-from-nestle-health-science-following-fda-approval-of-vowst\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230530005506r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230530005506r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seres-therapeutics-announces-receipt-of-125-million-milestone-from-nestle-health-science-following-fda-approval-of-vowst\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Seres Therapeutics Announces Receipt of $125 Million Milestone From Nestl\u00e9 Health Science Following FDA Approval of VOWST\u2122"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/760806","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=760806"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/760806\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=760806"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=760806"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=760806"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}